Table 1. Targeting B cells in cGVHD... | American Society of Hematology

Table 1.

Targeting B cells in cGVHD

Target name	Normal function	Name of drugs tested	Species analyzed	Evidence for role in cGVHD	Reference
BTK and ITK	Downstream of BCR activation	Ibrutinib	Mouse	Yes	14,58
BTK and ITK	Downstream of BCR activation	Ibrutinib	Human	Yes	59
CD20	B-cell surface antigen	Rituximab	Mouse	Yes (effective only in prevention)	49
CD20	B-cell surface antigen	Rituximab	Human	Yes	46,50,-52
CD30	B cells express CD30	Brentuximab	Human	Clinical trials ongoing	74
IL-6 receptor	IL-6 induces proliferation of pre–B cells	Tocilizumab	Human	Clinical trials ongoing	55
JAK 1/2	JAK1/2 mediate downstream effects of cytokine and chemokine receptors in B cells⁶³	Ruxolitinib	Mouse	Yes	64
			Retrospective clinical data	Yes	64
			Prospective phase 3 trial ongoing	Clinical trials ongoing	65
Plasma cells	Production of immunoglobulin that causes organ damage in cGVHD	Pomalidomide	Human	Clinical trials ongoing	53
Proteasome	Activation of the proteasome is important in plasma cells	Bortezomib	Mouse	Yes	75
Proteasome	Activation of the proteasome is important in plasma cells	Bortezomib	Human	Clinical trials ongoing	76
Proteasome	Activation of the immunoproteasome is important in plasma cells	Carfilzomib	Human	Clinical trials ongoing	77
ROCK2	T-cell activation with pSTAT3 and pSTAT5 effects B-cell migration	KD025	Mouse	Yes	61
			Mouse	Decreases Tfhs
			Human	Clinical trials ongoing	62
SYK	Downstream of BCR activation Cell migration Endocytosis	Entospletinib Fostamatinib	Mouse	Yes	10,13
SYK	Downstream of BCR activation Cell migration Endocytosis	Entospletinib Fostamatinib	Mouse	Clinical trials ongoing	57

Target name	Normal function	Name of drugs tested	Species analyzed	Evidence for role in cGVHD	Reference
BTK and ITK	Downstream of BCR activation	Ibrutinib	Mouse	Yes	14,58
BTK and ITK	Downstream of BCR activation	Ibrutinib	Human	Yes	59
CD20	B-cell surface antigen	Rituximab	Mouse	Yes (effective only in prevention)	49
CD20	B-cell surface antigen	Rituximab	Human	Yes	46,50,-52
CD30	B cells express CD30	Brentuximab	Human	Clinical trials ongoing	74
IL-6 receptor	IL-6 induces proliferation of pre–B cells	Tocilizumab	Human	Clinical trials ongoing	55
JAK 1/2	JAK1/2 mediate downstream effects of cytokine and chemokine receptors in B cells⁶³	Ruxolitinib	Mouse	Yes	64
			Retrospective clinical data	Yes	64
			Prospective phase 3 trial ongoing	Clinical trials ongoing	65
Plasma cells	Production of immunoglobulin that causes organ damage in cGVHD	Pomalidomide	Human	Clinical trials ongoing	53
Proteasome	Activation of the proteasome is important in plasma cells	Bortezomib	Mouse	Yes	75
Proteasome	Activation of the proteasome is important in plasma cells	Bortezomib	Human	Clinical trials ongoing	76
Proteasome	Activation of the immunoproteasome is important in plasma cells	Carfilzomib	Human	Clinical trials ongoing	77
ROCK2	T-cell activation with pSTAT3 and pSTAT5 effects B-cell migration	KD025	Mouse	Yes	61
			Mouse	Decreases Tfhs
			Human	Clinical trials ongoing	62
SYK	Downstream of BCR activation Cell migration Endocytosis	Entospletinib Fostamatinib	Mouse	Yes	10,13
SYK	Downstream of BCR activation Cell migration Endocytosis	Entospletinib Fostamatinib	Mouse	Clinical trials ongoing	57

Presented in alphabetical order.